Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s analysts explain why they aren’t buying it.The team also discusses what lessons can be learned from the regulatory roller-coaster ride of Replimune’s RP1 vusolimogene oderparepvec and psychedelic therapies’ inflection point in treating depression.View full story: https://www.biocentury.com/article/660376#BiotechMA #FDA #Psychedelics #Depression #OncolyticVirus00:00 - Introduction00:51 - AZ-BMS Rumors08:07 - Replimune20:46 - PsychedelicsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text